Brief: 4Dmt Highlights Recent Clinical Pipeline Progress, Near-Term Milestones

4D Molecular Therapeutics

04/01/2024 13:56

Jan 4 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4DMT HIGHLIGHTS RECENT CLINICAL PIPELINE PROGRESS,
NEAR-TERM
MILESTONES AND ORGANIZATIONAL UPDATES
    * WELL CAPITALIZED ENDING 2023 WITH $300 MILLION IN
ESTIMATED CASH
    * FINANCIAL RUNWAY GUIDANCE UNCHANGED AND CASH EXPECTED TO
BE
SUFFICIENT TO FUND OPERATIONS INTO H1 2026
    * EXPECT TO INITIATE CLINICAL DEVELOPMENT OF 4D-175 IN
GEOGRAPHIC
ATROPHY BY SECOND HALF OF YEAR

Source text for Eikon:  ID:nGNX8dRNKH 
Further company coverage:  FDMT.O 

 ((Reuters.Briefs@thomsonreuters.com;))